Product Description
DNL151 is an orally available, brain-penetrant inhibitor of the leucine-rich repeat kinase 2 (LRRK2). It started out as a backup to Denali’s lead LRRK2 inhibitor, DNL201; but it is now is its lead candidate after development of DNL201 was stopped in 2020. (Sourced from: https://www.alzforum.org/therapeutics/dnl151)
Mechanisms of Action: LRRK2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: Denali Therapeutics
Clinical Description

Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
LRRK2-PD | P2 |
Recruiting |
Parkinson's Disease |
2026-04-30 |